Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CelluJuve is a cellulose-based, plant-derived dermal filler solution under development by Spiderwort Biotechnologies. It is designed to provide structural support for soft tissue augmentation and rejuvenation, working with the body’s own proteins to create a natural look and feel by providing a framework for collagen deposition. Unlike many traditional fillers, CelluJuve is formulated without crosslinkers and aims to promote healthy tissue growth within its scaffolds. The product has demonstrated high biocompatibility in preclinical studies—being non-toxic, non-sensitizing, non-mutagenic, and classified as a non-irritant in human skin testing. Its initial clinical target is nasolabial fold remediation (wrinkle correction), but it may be applicable for broader cosmetic restoration purposes[1][3][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CelluJuve.